Ovid Looks To Epilepsy – And Beyond – For Candidate OV350

Ovid anticipates its deal to sell part of its interest in soticlestat milestones and royalties to Ligand will take it through 2026, while it looks to develop its KCC2-targeting OV350 for psychiatric disorders.